Aktienresearch · Der lange Blick

Investment-Research durch die Brille eines langfristigen Eigentümers

Das Zen Horizon Framework, das Geschäftsqualität, Burggräben und inneren Wert von KI, Technologie und globalen Aktien seziert — mit einer klaren Einschätzung der Sicherheitsmarge.

1240 Analysen15 Themen1186 Titel

Neueste Analysen

Mehr Analysen

54/100 58Buffett Beobachten Eli Lilly: A 43% ROIC Incretin Leader Priced for ≈ 18% a Year EPS Growth, with No Margin of Safety at USD 1,417.54 Eli Lilly is a US innovative drugmaker whose incretins Mounjaro and Zepbound generated 66% of Q3 2026 revenue. Q3 2026 revenue rose 39% to USD 24,397M on 53% volume growth while realized price fell 15%, and 2026 revenue guidance has been raised to USD 91–92B; at USD 1,417.54 the price needs ≈ 18%/yr EPS compounding against falling prices. Rating Watch: the price sits above the USD 970–1,312 hold zone with no margin of safety, and the ideal buy zone is USD 492–547. Eli Lilly and CompanyLLY · USAPharmaceuticals1. November 2026 45/100 72Buffett Beobachten Sungrow Power Supply: Q3 Profit Fell 67.67% as Margins Relapsed, and at CNY 65.29 the Shares Still Sit 48% Above Conservative Value Sungrow is a founder-controlled maker of solar inverters and grid-scale battery storage systems, and storage was 50.0% of its H1 2026 revenue. Q3 2026 broke the second-quarter recovery: attributable net income fell 67.67% year on year to CNY 1.34 bn and group gross margin slipped to about 29.4% from 38.6% in Q2, while US and EU market barriers keep widening. Rating Watch: at CNY 65.29 the price is 48% above the CNY 44.2 conservative value, so there is no margin of safety, and the ideal buy zone is CNY 32–35. Sungrow Power Supply Co., Ltd.300274 · ShenzhenPower Equipment31. Oktober 2026 48/100 67Buffett Beobachten SG Micro: 42.7% H1 Growth at a 51.84% Gross Margin Proves Share and Content Gains, but the A Share at CNY 120.55 Is 105x Trailing Earnings and Above the CNY 89 Base Value SG Micro is a Beijing fabless-plus analog chip designer whose more than 7,200 saleable products span signal chain, power management and sensors, with about 94% of revenue sold through distributors. H1 2026 revenue rose 42.7% to CNY 2.60 billion and recurring profit 164.6% at a 51.84% gross margin as optical modules lifted network and computing to about 25% of sales, yet CNY 1.68 billion of net inventory, share-based pay of about 24% of attributable profit and an undisclosed distributor channel mean the quality problem has changed rather than disappeared. Rating Watch: the A share at CNY 120.55 trades at about 105 times trailing attributable earnings and above the CNY 89 base-case value with no margin of safety; the ideal buy price is CNY 42–48 and the acceptable hold range CNY 78–100. SG Micro Corp300661 · ShenzhenAnalog Chips28. September 2026 39/100 Halten Kubota Corporation: A ¥70bn Tariff Refund Lifts the FY2026 Margin to 12.2% from 10.1%, and ¥2,751.5 Sits 28–38% Above the ¥2,000–2,150 Conservative Value Kubota is an Osaka-based machinery group built around compact farm equipment, engines and construction machinery: Farm & Industrial Machinery produced 88.6% of H1 2026 revenue, North America supplied 42.1%, and a captive-finance book carried ¥2.23 trillion of finance receivables at June 2026. FY2026 guidance of ¥400 billion operating profit and a 12.2% margin includes about ¥70 billion of non-recurring US tariff refunds, so the company's own ex-refund margin is 10.1%, while operating cash flow over FY2021 to FY2025 was only 0.69 times cumulative parent net income and cumulative reported free cash flow was around negative ¥314 billion. Rating Hold: at ¥2,751.5 the shares trade at 10.8 times guided EPS but closer to 13 times refund-normalized earnings and 28–38% above the ¥2,000–2,150 conservative value, so the margin of safety is none and the ideal buy price is ¥1,550 to ¥1,650. Kubota Corporation6326 · TSEConstruction Machinery28. September 2026

Insights

Alle Insights

Ausgewählte Themen

Alle 15 Themen

Die globale Rüstungslieferkette

54 Titel

Von Spezialwerkstoffen bis zu den großen Systemhäusern: die komplette Lieferkettenkarte des Aufrüstungszyklus

Krebs · Seltene Erkrankungen · Schwer behandelbare Grenzgebiete

108 Titel

Zielgerichtete / Immun- / Zell- / Gen- / Nukleinsäure- / Radiopharmazeutika: eine Karte der Frontier-Therapien gegen Krankheiten mit hohem ungedecktem Bedarf, samt der globalen und chinesischen Akteure, die sie entwickeln

Nischenchampions in jeder Branche

90 Titel

Unternehmen, die eine schmale Nische beherrschen, weltweit auf Platz eins oder unter den Top drei rangieren und über echte Preissetzungsmacht verfügen: Nischenchampions an kritischen Gliedern der Wertschöpfungskette. Der Rahmen folgt Hermann Simons "Hidden Champions", lockert jedoch dessen Schwellen für Größe und Bekanntheit (keine Obergrenze bei der Größe, keine Pflicht zur Zurückhaltung in der Öffentlichkeit). Entscheidend ist, wie schmal die Nische ist und wie tief die Position verankert, dargestellt über acht funktionale Domänen hinweg.

Eine von dir verfolgte Aktie nicht dabei? Individuelle Analyse anfordern